Connect with us

Politics

United Nations Panel Releases First-Ever Review of Marijuana

Published

on

For the first time ever, a World Health Organization (WHO) committee is reviewing marijuana’s status under international law. And technical documents the committee recently released include several positive, evidentiary findings about the plant’s medical value.

The committee’s pre-review—which will be formally unveiled at its meeting next week—could ultimately go on to influence international drug policy, as well as the classification of cannabis under the laws of individual nations.

The moves by the WHO’s Expert Committee on Drug Dependence (ECDD) come about a month after the United States government requested public input on marijuana scheduling at the international level. That resulted in the submission of more than 17,000 comments that the Food and Drug Administration indicated would be used to inform the U.S.’s response and recommendations to WHO, which is part of the United Nations.

In addition to reaffirming its earlier findings that CBD is a low-risk cannabinoid that provides demonstrably positive health benefits for patients in a critical review, WHO’s new documents also look at the science of marijuana overall and examined cannabis tinctures and extracts, THC and THC isomers.

Here’s what the committee found

In terms of the potential risks of marijuana use, the committee first acknowledged that nobody has ever died from an acute marijuana overdose and described cannabis as a “relatively safe drug.”

Research indicating that marijuana use was associated with a greater risk of adverse cardiovascular events “appears at best to be weak,” the committee wrote.

Notably, the committee also cited a “wealth of preclinical literature” that shows cannabinoids “reduce cancer cell proliferation” and inhibit “cancer cell migration and angiogenesis in numerous cancer cell types.”

The therapeutic benefits of cannabis

Getting into medical properties, the committee’s pre-review examined several health conditions that often qualify patients for medical marijuana in jurisdictions that have legalized it. Those conditions include: appetite stimulation, chronic pain, epilepsy, neuropathic pain, opioid withdrawal, post-traumatic stress disorder and sleep disorders.

The committee’s review of existing scientific literature on the effectiveness of cannabis treatment for these and other conditions found evidence that cannabinoids reduce pain, promote sleep and improve motor function for individuals with Parkinson’s disease. However, one common theme in the pre-review was that not enough clinical research had been conducted for the committee to make a determination about the potential health benefits of cannabis for multiple conditions.

Michael Krawitz, a U.S. Air Force veteran and legalization activist who has worked for years to reform international treaties on marijuana, told Marijuana Moment that the evidence about marijuana’s medical benefits included in the review was insufficient. He said it was reflective of the “creeping slow nature of the international bodies,” which have not viewed marijuana reform as “a priority.”

“Why did it take so long?” Krawitz said. “Why is it 2018 and they’re just now reviewing a treaty that should have been reviewed in the ‘70s or the ‘80s or the ‘90s?”

In some respects, the research situation is a bit of a catch-22. Part of the reason for the lack of clinical research into marijuana is that it’s prohibited under international treaties, which bar United Nations (UN) member states from legalizing cannabis for non-medical or scientific reasons.

“Often, the U.S. government hid behind its obligations under the Single Convention to avoid expanding research into illicit substances, even as scientific and medical exceptions to prohibition were explicitly spelled out in the U.N. treaty for marijuana and other drugs,” the Brookings Institution’s John Hudak explained.

The last section of the new pre-review deals with the epidemiology of marijuana. While recognizing that cannabis “has some therapeutic potential,” the review also raised concerns about several short-term and long-term effects of use, which “may be relevant to public health.”

The acute effects, according to the commission, include “[c]ognitive effects including impaired short-term memory, altered judgement and impaired motor coordination, which increase the risk of injuries (best studied with traffic injuries under the influence of cannabis, where causality has been established despite some negative epidemiological results)” and “altered judgement,” which “may also lead to problematic decisions with respect to increasing risk of sexually transmitted diseases.”

The committee determined that heavy, frequent use was also associated with “[i]mpairment of the brain (especially of the adolescent brain),” “[p]oor educational outcome and partially lasting cognitive impairments, with increased likelihood of dropping out of school” and “[i]ncreased risk of chronic psychosis disorders (including schizophrenia) in persons with a predisposition to such disorders.”

Why this pre-review matters

Reform advocates hope that the pre-review will be accepted and there will be a subsequent call for a more in-depth critical review. That would involve a deliberative process allowing experts to provide the committee with new information before a final recommendation on cannabis’s status would be made to UN Secretary-General António Guterres.

Guterres is a supporter of broad drug policy reform. As Portugal’s prime minister, he oversaw the enactment of a law decriminalizing marijuana and other drugs. In a March speech before the UN’s drug policy body, he touted the success of that policy.

Krawitz said an ideal outcome of the current review would be a committee recommendation to remove cannabis from the international treaty’s list of schedule 4 drugs, which could ultimately free up member states to push ahead with their own reform efforts.

UN Chief Touts Drug Decriminalization In Speech To Narcotics Commission

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Los Angeles-based associate editor. His work has also appeared in High Times, VICE and attn.

Politics

Kentucky GOP Congressman Touts ‘High Hemp IQ’ Of His Constituents

Published

on

Rep. James Comer (R-KY) says that he proved his political advisors wrong when he decided to champion hemp legalization.

When he served as Kentucky’s Agriculture Commissioner before joining Congress and first contemplated “making hemp a reality,” he was told that people would conflate the crop with marijuana and he’d face a backlash, Comer said during an interview that aired this week.

“They said the people of Kentucky will never know the difference. They’ll think you’re talking about marijuana and you’re done,” he said during the Kentucky Educational Television appearance. “You can’t be a Republican and do this.”

“But people in Kentucky are smarter than some people give us credit for, and the people in Kentucky knew the history of hemp,” he said, noting that his own grandparents cultivated the crop.

“We have a high hemp IQ in Kentucky, and people across America are now learning the difference between hemp and marijuana.”

One of the areas that Comer said he hopes to see expanded is the use of hemp fibers to create products such as furniture and car parts. He mentioned one example of a Kentucky company that’s creating hardwood flooring out of hemp, and House Agriculture Committee Chair Collin Peterson (D-MN) is going to tour that facility with him soon.

Shortly before becoming the panel’s chair, Peterson said he was considering growing hemp on his own farm.

Most of the existing hemp facilities in Kentucky are producing CBD oil, which Comer said he also takes to treat minor pain.

While hemp and its derivatives were federally legalized under the 2018 Farm Bill, businesses are still awaiting guidelines from the U.S. Department of Agriculture (USDA) and the Food and Drug Administration (FDA). And that regulatory uncertainty has led some financial institutions to deny credit lines to hemp companies.

To that end, Comer said he and Senate Majority Leader Mitch McConnell (R-KY) are working closely to resolve the problem. That includes pushing for the Secure And Fair Enforcement (SAFE) Banking Act, which would protect banks that service state-legal cannabis businesses from being penalized by federal financial regulators.

“We teamed up with the marijuana people in the states,” Comer said.

Watch Comer’s hemp comments, starting around 5:30 into the video below:

“They’ve legalized marijuana. They’re selling marijuana. They’re not allowed to deposit the cash. They’re not allowed to take credit card transactions at those marijuana stores,” he said. “We have worked with them to try to create a system where you can have financial transparency, and that bill is making its way through Congress now.”

The SAFE Banking Act was approved by the House Financial Services Committee in March. And on Tuesday, the Senate Banking Committee took advocates by surprise after it announced that it would hold a hearing on marijuana banking issues next week, with just days left before the August recess.

Separately, the Senate Agriculture Committee will meet to discuss hemp production two days later.

McConnell has been an especially vocal advocate for hemp and CBD. For example, he led the head of USDA on a tour of a Kentucky hemp facility that produces CBD oil earlier this month.

Comer also claimed in the new interview that large pharmaceutical companies feel threatened by hemp-derived CBD as more consumers gravitate toward it as a “natural supplement” that could be a substitute for prescription painkillers.

“Now what you are having up here in Washington as we speak, the big drug companies are like, ‘Wow, people are buying this CBD oil and not buying our drug,'” the congressman said. “So they’re demanding that the FDA regulate it.”

He and McConnell are working to “keep the FDA off the backs of people,” Comer said.

While former FDA Commissioner Scott Gottlieb stressed that creating a regulatory pathway that allows for the lawful marketing of CBD as a food item or dietary supplement would take years without congressional action, the agency recently said that it is speeding up the rulemaking process and will issue a progress report by early fall.

USDA similarly recognized the intense interest from lawmakers and stakeholders in developing regulations for the crop, and it plans to issue an interim final rule for the crop in August.

Senate Schedules Second Cannabis Hearing For Next Week

Photo courtesy of KET.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Psychedelics Decriminalization Moves Forward In Cities Around The U.S.

Published

on

Activists in Berkeley, California and Port Townsend, Washington took steps this week to get psilocybin mushrooms and other psychedelics decriminalized, following in the footsteps of successful similar efforts in Denver and Oakland.

In Berkeley, a decriminalization resolution advanced in a City Council committee on Wednesday, and organizers in Port Townsend spoke about their proposal at a county public health board meeting on Thursday, with plans to formally present it to the City and County Council.

The Berkeley measure would prohibit city departments and law enforcement from using any funds to enforce laws against possession, propagation and consumption of psychedelics by individuals 21 or older. Members of the City Council Public Safety committee unanimously voted to send the resolution to the body’s Public Health Committee for further consideration.

If that panel approves the measure, the full Council will schedule a hearing and vote on final passage. Decriminalize Nature, the group behind this resolution as well as the successful passage of neighboring Oakland’s psychedelics decriminalization effort last month, said they hope the Council will act on the measure by early November.

Separately, activists in Port Townsend announced that they delivered a speech about their psychedelics decriminalization proposal during a meeting of the Jefferson County Board of Health.

Beyond prohibiting the use of government funds to criminalize adults for using and possessing the substances, the local Washington resolution also calls on the city administrator to “instruct the City’s state and federal lobbyists to work in support of decriminalizing all Entheogenic Plants and plant-based compounds that are listed on the Federal Controlled Substances Schedule 1.”

“We are overwhelmed by the support of our community. Our group of supporters filled up half the audience,” the Port Townsend Psychedelic Society said in an Instagram post. “We are currently making plans to speak with the county health officer to talk about next steps in presenting in front of city and county council.”

Alex Williams, who is leading the decriminalization effort in Berkeley, told Marijuana Moment that Wednesday’s Council committee meeting there “went better than I had anticipated” and that he feels “there is an excellent chance of the resolution passing.”

Watch the Berkeley Public Safety Committee discuss psychedelics, starting at about 42:00:

While Williams said two members of the committee seemed to be under the impression that the resolution is singularly geared toward recreational use and meant to “capitalize on a new market,” Decriminalize Nature plans to address those misconceptions, emphasizing that the measure would not provide for commercial manufacturing or sales and that “this process is very important to allowing safe, equitable access to marginalized communities.”

“It is essential that entheogenic substances be treats as sacred spiritual practices and healers,” he added.

The resolution defines entheogenic substances as “plants and natural sources such as mushrooms, cacti, iboga containing plants and/or extracted combinations of plants similar to ayahuasca; and limited to those containing the following types of compounds: indoleamines, tryptamines, phenethylamines.”

Two Councilmembers, Rigel Robinson and Cheryl Davila, are sponsoring the measure.

“You can imagine a day where, years from now, doctors working with patients with serious depression or veterans dealing with PTSD could actually offer them a more realistic and comprehensive suite of potential treatments, which may include some of these plants as the research over the last several decades has indicated,” Robinson said at the meeting.

While Berkeley might seem like an obvious target for psychedelics reform given the city’s decades-long close association with counterculture, the movement to remove criminal penalties is gaining steam nationally. Decriminalize Nature is maintaining a map of jurisdictions throughout the country where activists have expressed interest in pursuing a similar model.

Also this week, a resident spoke at a Columbia, Missouri City Council meeting, asking the body to consider a resolution to decriminalize psychedelics. At least one councilmember expressed interest in following through, and he called the therapeutic potential of the natural substances “very promising.”

Individuals from nearly 100 cities have reached out to the organization for assistance advancing their own decriminalization efforts.

Voters in Denver kicked things off by approving the nation’s first-ever ballot measure to decriminalize psilocybin mushrooms in May.

Activists are currently pursuing efforts to place psilocybin-focused measures on statewide ballots in California and Oregon for next year.

More Than 100 Marijuana Businesses Urge Congress To Include Social Equity In Legalization

Photo courtesy of Wikimedia/Mushroom Observer.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Top Democratic Party Leader Flops With Attempted Joke About Trump Smoking Hemp

Published

on

The chairman of the Democratic National Committee (DNC) apparently thinks that hemp gets you high—and that getting high makes you dumb.

In an attempted dig at President Donald Trump, who said last week that farmers struggling amid a trade war were “over the hump,” DNC Chair Tom Perez said he thought the president “was smoking some hemp when he said they were over the hump.”

“If you smoke some hemp, I guess that would stimulate certain farm economies here,” he added during his remarks at a press conference in Wisconsin.

Watch Perez’s hemp comment at about 6:45 into the video below:

Because hemp contains only trace amounts of THC, the main psychoactive ingredient in marijuana, it wouldn’t get you high, as Perez implied. But legalization advocates say it’s especially problematic that a party leader is treating marijuana as a laughing matter in the first place.

“I would need to be smoking something a hell of a lot stronger than hemp to find Tom Perez’s weak attempt at a marijuana joke funny,” Erik Altieri, executive director of NORML, told Marijuana Moment.

“At a time when over 600,000 overwhelmingly black and brown Americans are still being arrested every year for simple possession, our failed and racist prohibition is no laughing matter,” he said. “While we have made great progress in winning elected officials nationwide to our cause, Perez illustrated that we have a lot of work left to do when it comes educating them about the issue and still a bit of a road to go down before we can stop dealing with dad jokes and bad weed puns.”

Don Murphy, director of federal policies for the Marijuana Policy Project, echoed that point.

“We need more leadership and action at the federal level, not more stupid jokes, puns and inaccurate comments about hemp’s ability to get you high,” he told Marijuana Moment. “Luckily that is something that many of his party’s presidential candidates understand,” he said. “Sadly, Mr. Perez does not.”

Perez’s position on cannabis policy isn’t quite clear, as he’s remained largely silent on the issue. In contrast, many 2020 Democratic presidential candidates are campaigning on broad marijuana reform proposals.

The DNC chair made his attempted hemp quip during a press availability in Milwaukee, where he is meeting donors and coordinating preparation for next year’s Democratic National Convention.

Senate Schedules Second Cannabis Hearing For Next Week

Photo courtesy of Flickr/Gage Skidmore.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Stay Up To The Moment

Marijuana News In Your Inbox


Support Marijuana Moment

Marijuana News In Your Inbox

Do NOT follow this link or you will be banned from the site!